

## Income statement

Three months ended 31st March 2010

	Total Q1 2010 £m	Total Q1 2009 £m	Growth	
			CER%	£%
<b>TURNOVER</b>	<b>7,357</b>	6,769	<b>13</b>	<b>9</b>
Cost of sales	<b>(1,952)</b>	(1,787)	<b>11</b>	<b>9</b>
Gross profit	<b>5,405</b>	4,982	<b>14</b>	<b>8</b>
Selling, general and administration	<b>(2,350)</b>	(2,200)	<b>17</b>	<b>7</b>
Research and development	<b>(1,160)</b>	(1,124)	<b>7</b>	<b>3</b>
Other operating income	<b>199</b>	54		
<b>OPERATING PROFIT</b>	<b>2,094</b>	1,712	<b>22</b>	<b>22</b>
Finance income	<b>17</b>	28		
Finance expense	<b>(205)</b>	(203)		
Profit on disposal of interest in associate	<b>-</b>	115		
Share of after tax profits of associates and joint ventures	<b>25</b>	14		
<b>PROFIT BEFORE TAXATION</b>	<b>1,931</b>	1,666	<b>15</b>	<b>16</b>
Taxation	<b>(536)</b>	(497)		
<i>Tax rate %</i>	<b>27.8%</b>	29.8%		
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>	<b>1,395</b>	1,169	<b>19</b>	<b>19</b>
Profit attributable to non-controlling interests	<b>55</b>	38		
Profit attributable to shareholders	<b>1,340</b>	1,131		
	<b>1,395</b>	1,169		
<b>EARNINGS PER SHARE</b>	<b>26.4p</b>	22.3p	<b>18</b>	<b>18</b>
Diluted earnings per share	<b>26.1p</b>	22.2p		

**Pharmaceuticals turnover**  
**Three months ended 31st March 2010.**

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>1,766</b>	<b>6</b>	<b>2</b>	<b>805</b>	<b>3</b>	<b>(5)</b>	<b>569</b>	<b>6</b>	<b>4</b>	<b>392</b>	<b>13</b>	<b>14</b>
<i>Avamys/Veramyst</i>	46	52	48	17	(10)	(15)	13	56	44	16	>100	>100
<i>Flixonase/Flonase</i>	45	(30)	(35)	6	(40)	(40)	10	(17)	(17)	29	(32)	(38)
<i>Flixotide/Flovent</i>	196	5	1	99	8	-	45	(6)	(6)	52	8	8
<i>Seretide/Advair</i>	1,264	9	4	630	4	(4)	423	10	7	211	25	26
<i>Serevent</i>	51	(16)	(18)	16	(11)	(16)	26	(16)	(16)	9	(25)	(25)
<i>Ventolin</i>	116	3	-	35	-	(8)	37	-	-	44	7	7
<i>Zyrtec</i>	20	17	11	-	-	-	-	-	-	20	17	11
<b>Anti-virals</b>	<b>358</b>	<b>(44)</b>	<b>(46)</b>	<b>154</b>	<b>(42)</b>	<b>(47)</b>	<b>35</b>	<b>(78)</b>	<b>(79)</b>	<b>169</b>	<b>(20)</b>	<b>(21)</b>
<i>Relenza</i>	84	(60)	(62)	30	>100	>100	2	(97)	(98)	52	(49)	(49)
<i>Valtrex</i>	176	(46)	(49)	107	(55)	(58)	23	(43)	(45)	46	-	2
<i>Zeffix</i>	52	4	(2)	3	-	(25)	7	-	-	42	5	-
<b>Central nervous system</b>	<b>417</b>	<b>(13)</b>	<b>(16)</b>	<b>136</b>	<b>(32)</b>	<b>(37)</b>	<b>140</b>	<b>(2)</b>	<b>(3)</b>	<b>141</b>	<b>7</b>	<b>2</b>
<i>Imigran/Imitrex</i>	57	(9)	(11)	24	(11)	(14)	22	(12)	(12)	11	-	-
<i>Lamictal</i>	120	(11)	(17)	61	(23)	(29)	37	(3)	(5)	22	26	16
<i>Requip</i>	55	14	10	10	38	25	36	13	13	9	-	(10)
<i>Seroxat/Paxil</i>	106	(12)	(16)	10	(29)	(29)	22	(21)	(21)	74	(6)	(12)
<i>Treximet</i>	13	7	(7)	13	-	(7)	-	-	-	-	-	-
<i>Wellbutrin</i>	20	(67)	(69)	8	(85)	(85)	9	50	50	3	-	(25)
<b>Cardiovascular and urogenital</b>	<b>570</b>	<b>9</b>	<b>3</b>	<b>337</b>	<b>6</b>	<b>(2)</b>	<b>153</b>	<b>11</b>	<b>9</b>	<b>80</b>	<b>23</b>	<b>21</b>
<i>Arixtra</i>	70	25	19	39	27	18	26	23	18	5	25	25
<i>Avodart</i>	139	20	14	76	12	4	40	17	11	23	77	77
<i>Coreg</i>	42	(12)	(18)	42	(12)	(18)	-	-	-	-	-	-
<i>Fraxiparine</i>	56	4	2	-	-	-	43	-	-	13	17	8
<i>Lovaza</i>	107	9	1	107	10	2	-	-	-	-	-	-
<i>Vesicare</i>	25	13	4	25	13	4	-	-	-	-	-	-
<i>Volibris</i>	9	>100	>100	-	-	-	8	>100	>100	1	-	-
<b>Metabolic</b>	<b>230</b>	<b>(18)</b>	<b>(22)</b>	<b>89</b>	<b>(36)</b>	<b>(41)</b>	<b>61</b>	<b>(7)</b>	<b>(10)</b>	<b>80</b>	<b>7</b>	<b>5</b>
<i>Avandia products</i>	169	(10)	(14)	89	(14)	(21)	38	(12)	(12)	42	2	-
<i>Bonviva/Boniva</i>	23	(63)	(63)	-	-	-	20	(5)	(5)	3	-	-
<b>Anti-bacterials</b>	<b>356</b>	<b>(6)</b>	<b>(9)</b>	<b>24</b>	<b>(10)</b>	<b>(17)</b>	<b>142</b>	<b>(21)</b>	<b>(22)</b>	<b>190</b>	<b>10</b>	<b>5</b>
<i>Augmentin</i>	160	(10)	(14)	8	(44)	(50)	63	(23)	(25)	89	9	3
<b>Oncology and emesis</b>	<b>169</b>	<b>23</b>	<b>17</b>	<b>92</b>	<b>41</b>	<b>31</b>	<b>50</b>	-	<b>(2)</b>	<b>27</b>	<b>17</b>	<b>17</b>
<i>Arzerra</i>	5	-	-	5	-	-	-	-	-	-	-	-
<i>Hycamtin</i>	40	-	(7)	24	-	(8)	13	(7)	(13)	3	50	50
<i>Promacta</i>	6	>100	>100	6	>100	>100	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	53	62	56	17	73	55	24	41	41	12	100	100
<i>Votrient</i>	5	-	-	5	-	-	-	-	-	-	-	-
<b>Vaccines</b>	<b>1,411</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>171</b>	<b>55</b>	<b>44</b>	<b>613</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>627</b>	<b>&gt;100</b>	<b>&gt;100</b>
<i>Boostrix</i>	30	19	15	15	55	36	9	25	13	6	(43)	(14)
<i>Cervarix</i>	77	60	60	2	-	-	59	51	51	16	78	78
<i>Fluarix, FluLaval</i>	5	(43)	(29)	1	-	-	-	-	-	4	(50)	(33)
<i>Flu Pandemic</i>	698	>100	>100	-	-	-	304	>100	>100	394	>100	>100
<i>Hepatitis</i>	197	38	32	92	92	77	61	2	-	44	19	22
<i>Infanrix, Pediarix</i>	166	(3)	(5)	32	(13)	(18)	104	(2)	(5)	30	4	11
<i>Rotarix</i>	65	19	14	27	93	80	13	8	-	25	(14)	(14)
<i>Synflorix</i>	45	-	-	-	-	-	12	-	-	33	-	-
<b>Dermatologicals</b>	<b>265</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>97</b>	<b>100</b>	<b>&gt;100</b>	<b>62</b>	<b>&gt;100</b>	<b>100</b>	<b>106</b>	<b>83</b>	<b>83</b>
<i>Bactroban</i>	27	(7)	(10)	11	(20)	(27)	6	-	-	10	11	11
<i>Dermovate</i>	15	-	-	-	-	-	4	-	-	11	-	-
<i>Duac</i>	27	-	-	17	-	-	6	-	-	4	-	-
<i>Soriatane</i>	18	-	-	18	-	-	-	-	-	-	-	-
<i>Zovirax</i>	49	61	58	26	>100	>100	7	(13)	(13)	16	(11)	(11)
<b>Other</b>	<b>211</b>	<b>20</b>	<b>17</b>	<b>4</b>	<b>(20)</b>	<b>(20)</b>	<b>68</b>	<b>24</b>	<b>24</b>	<b>139</b>	<b>20</b>	<b>16</b>
	<b>5,753</b>	<b>15</b>	<b>11</b>	<b>1,909</b>	<b>(1)</b>	<b>(9)</b>	<b>1,893</b>	<b>16</b>	<b>13</b>	<b>1,951</b>	<b>39</b>	<b>35</b>
<b>ViiV Healthcare (HIV)</b>	<b>373</b>	<b>(7)</b>	<b>(11)</b>	<b>159</b>	<b>(11)</b>	<b>(18)</b>	<b>159</b>	<b>(3)</b>	<b>(5)</b>	<b>55</b>	<b>(4)</b>	<b>(2)</b>
<i>Combivir</i>	82	(23)	(27)	34	(30)	(36)	33	(17)	(20)	15	(17)	(17)
<i>EpiVir</i>	28	(15)	(18)	10	(15)	(23)	10	(21)	(29)	8	-	14
<i>Epzicom/Kivexa</i>	131	(1)	(4)	48	(10)	(17)	64	6	3	19	6	12
<i>Lexiva</i>	41	(8)	(15)	21	(15)	(22)	15	(12)	(12)	5	50	25
<i>Selzentry</i>	19	-	-	8	-	-	11	-	-	-	-	-
<i>Trizivir</i>	38	(27)	(32)	19	(33)	(37)	17	(29)	(11)	2	100	-
	<b>6,126</b>	<b>14</b>	<b>9</b>									

Pharmaceutical turnover includes co-promotion income

## Consumer Healthcare turnover

Three months ended 31st March 2010.

	Total			USA			Europe			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Over-the-counter medicines</b>	<b>617</b>	<b>11</b>	<b>8</b>	<b>169</b>	<b>2</b>	<b>(6)</b>	<b>190</b>	<b>21</b>	<b>19</b>	<b>258</b>	<b>11</b>	<b>11</b>
<i>Alli</i>	63	>100	97	28	7	(3)	34	>100	>100	1	-	-
<i>Breathe Right</i>	21	(19)	(22)	11	(21)	(21)	5	(14)	(29)	5	(17)	(17)
Cold sore franchise	25	9	9	10	22	11	12	9	9	3	(33)	-
<i>Nicotine replacement</i>	92	16	12	62	16	7	19	12	12	11	29	57
<i>Panadol</i>	117	14	16	-	-	-	27	30	35	90	10	11
<i>Tums</i>	26	(7)	(13)	22	(11)	(19)	-	-	-	4	33	33
<b>Oral healthcare</b>	<b>381</b>	<b>5</b>	<b>4</b>	<b>77</b>	<b>6</b>	<b>(1)</b>	<b>179</b>	<b>(1)</b>	<b>(3)</b>	<b>125</b>	<b>16</b>	<b>18</b>
<i>Aquafresh franchise</i>	123	(3)	(4)	25	-	(7)	67	(8)	(8)	31	7	11
Biotene	7	17	17	5	-	-	1	-	-	1	-	-
Denture care	76	(3)	(5)	16	(11)	(16)	24	(11)	(14)	36	9	9
<i>Sensodyne franchise</i>	133	21	19	30	23	15	50	9	6	53	33	36
<b>Nutritional healthcare</b>	<b>233</b>	<b>12</b>	<b>10</b>	-	-	-	<b>102</b>	<b>7</b>	<b>7</b>	<b>131</b>	<b>16</b>	<b>13</b>
<i>Horlicks</i>	87	17	16	-	-	-	6	20	20	81	17	16
<i>Lucozade</i>	82	5	3	-	-	-	67	3	3	15	13	-
<i>Ribena</i>	42	11	11	-	-	-	29	16	16	13	-	-
	<b>1,231</b>	<b>9</b>	<b>7</b>	<b>246</b>	<b>3</b>	<b>(5)</b>	<b>471</b>	<b>9</b>	<b>8</b>	<b>514</b>	<b>13</b>	<b>13</b>